Settling on an Increased NCI Budget

Publication
Article
OncologyONCOLOGY Vol 14 No 10
Volume 14
Issue 10

The final numbers are not in yet, but there is no doubt that Congress will fund the National Cancer Institute (NCI) at a considerably higher level than the $3.505 billion the Clinton administration asked for. That fiscal 2001 request was already nearly 6% above the actual 2000 budget.

The final numbers are not in yet, but there is no doubt that Congress will fund the National Cancer Institute (NCI) at a considerably higher level than the $3.505 billion the Clinton administration asked for. That fiscal 2001 request was already nearly 6% above the actual 2000 budget. The House approved $3.793 billion and the Senate went one better—to $3.804 billion. At the end of July, a House and Senate conference committee agreed to a compromise budget number for all the NIH institutes. Those numbers were not available at press time but were planned for release by October. It is safe to assume that the NCI budget will be somewhere between the House and Senate number. The size of the increase, of course, is good news. But the House and Senate enumerated a number of specific cancer research areas they expected to get more attention.Those “earmarks” can sometimes cause problems between cancer advocacy groups. The House, for example, lists 18 separate areas it expects the NCI to get a move on, including esophageal and stomach cancers, endometrial and cervical cancers, lung cancer screening, and urologic cancers.

Related Videos
Amrita Y. Krishnan, MD, and Binod Dhakal, MD
Amrita Y. Krishnan, MD, and Binod Dhakal, MD
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
A panel of 4 experts on multiple myeloma
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Video 1 - 4 KOLs are featured in "Triaging and Prioritizing Patients with Multiple Myeloma"
Video 1 - 4 KOLs are featured in "CAR T-Cell Therapy: Leukapheresis Practices"
A panel of 4 experts on multiple myeloma
Related Content